Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944939 | 0.86 | NPC1 (0.37) | NPC1LMNARAB9ATAS1R3TAS1R1 | |
| SCHEMBL9944940 | 0.84 | RAB9A (0.36) | ALDH1A1NPC1RAB9ACD38TAS1R3 | |
| SCHEMBL9944896 | 0.81 | PTGES (0.41) | ALDH1A1NPC1LMNARAB9ACNR2 | |
| SCHEMBL9944783 | 0.81 | ALDH1A1 (0.40) | ALDH1A1NPC1RAB9ACD38TAS1R3 | |
| SCHEMBL9944785 | 0.81 | ALDH1A1 (0.40) | ALDH1A1NPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL9944780 | 0.80 | CNR2 (0.46) | ALDH1A1CNR2 | |
| SCHEMBL9944927 | 0.80 | ALDH1A1 (0.40) | ALDH1A1NPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL9944933 | 0.80 | ALDH1A1 (0.40) | ALDH1A1NPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL9944779 | 0.80 | ALDH1A1 (0.40) | ALDH1A1NPC1RAB9ATAS1R3TAS1R1 | |
| SCHEMBL9944941 | 0.79 | ALDH1A1 (0.35) | ALDH1A1NPC1RAB9ACD38CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | ALDH1A1 126/4885NPC1 1695/4885LMNA 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.